ArticleArchives of dermatological research2025
Evaluation of the serum level of Lipocalin 2 in vitiligo.
Article in Archives of dermatological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vitiligo is considered as depigmenting skin disorder where patches of skin losing their pigment. Lipocalin-2 (LCN2) is one of the Inflammatory adipokines that has a potential role in skin disorders and other inflammatory diseases as well. To measure the concentration level of LCN2 in vitiligo patients compared to healthy controls and to investigate its relation to disease activity and other clinical data to evaluate its role in the pathogenesis of the disease. Eighty individuals subdivided equally into two groups (vitiligo and controls) were enrolled in the study. The serum level of LCN2 was measured by ELISA where from all participants, a 5-mL venous blood was withdrawn in plain tube from each subject. There were high significant difference of LCN2 in serum between both groups where LCN2 was higher in vitiligo patients than than controls with mean and standard deviations of 399.2 ± 134.6 and 257.2 ± 42.5 respectively (p < 0.001). The level of LCN2 tended to increase in vitiligo patients with sudden onset than gradual patients showing a significant difference with p-value 0.030. Regarding the severity of the disease results showed that the level of LCN2 tended to increase in moderate and severe patients than mild but with no significant difference between the groups. LCN2 may play a vital role and a good marker for the early diagnosis and the pathogenesis of vitiligo disease.
Indexed as
Identifiers
39825941What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.